Back to top

Image: Bigstock

Express Scripts (ESRX) Dips on $3.6 Billion Deal to Buy EviCore Healthcare

Read MoreHide Full Article

On Tuesday, shares of Express Scripts Holding Co. are falling, down about 1.7% in late-morning trading after the company announced plans to purchase privately-held medical benefit management company eviCore Healthcare for $3.6 billion.

Express Scripts, which is the largest stand-alone pharmacy-benefits manager, hopes the deal will help grow its adjusted diluted earnings per share in the first full year of operation. The company also explained how the deal is “an attractive entry point into a growing market.”

EviCore works with health plans in order to decrease the number of medically unnecessary and expensive tests—think imaging scans— and manages medical benefits for 100 million people and has 4,000 employees.

"The rising cost of healthcare is one of the most important issues facing Americans today," Tim Wentworth, CEO of Express Scripts said in a statement. "Together with eviCore, Express Scripts will be an even more powerful partner in managing costs for patients and payers, bringing us closer to our goal of becoming the nation's leading patient benefit manager."

EviCore CEO John Arlotta thinks the two companies will be “uniquely positioned” to help improve healthcare issues. The company will operate as a standalone business unit within Express Scripts.

The deal also comes at an interesting time in the healthcare and pharmacy space, as leaders like Express Scripts await a possible decision from e-commerce player Amazon.com (AMZN - Free Report) , who may or may not move into pharmacy benefits (also read: Could Amazon Be the Next Big Pharmacy Giant?)

Express Scripts is buying eviCore from current investors that include General Atlantic, TA Associates, and Ridgemont Equity Partners. The deal is expected to close in the fourth quarter of 2017, but must be approved by regulators.

ESRX is currently a #3 (Hold) on the Zacks Rank, and shares of the company have fallen over 14% so far in 2017.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.  See Them Free>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Amazon.com, Inc. (AMZN) - free report >>